Navigation Links
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

ecently as Assistant Professor of Medical Oncology at the Lombardi Cancer Center, Georgetown University Medical Center. She received her Ph.D. from the Department of Physiology at Johns Hopkins University School of Medicine, her M.D. from the Medical College of Pennsylvania and a B.A. from Boston University.

Dr. Fox joined Sunesis in 2006 as Senior Director, Program Leader and will now have an expanded role as Vice President, Product and Preclinical Development. Previously, she served as Senior Director in the Translational Sciences Department for Chiron Corporation (now Novartis AG) from 2005 to 2006, where she led the clinical pharmacology and preclinical pharmokinetics (PK)/drug metabolism group, supporting the development of the company's novel oncology compounds. From 2002 to 2005, Dr. Fox was Senior Director/Senior Staff Scientist for Genencor International, where she started the Pharmacological Sciences Department. Dr. Fox's industry career began in the PK/Metabolism Department for Genentech, where she ultimately led the group responsible for all oncology projects from late-stage research through clinical development. This was preceded by leadership of the immunology focus area within the PK/Metabolism Department. During her ten years at Genentech, she contributed to the development of products such as Herceptin(R), Xolair(R), Raptiva(R) and Avastin(R). Dr. Fox received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology and an A.B. in Chemistry from Bryn Mawr College. She conducted postdoctoral research at The Rockefeller University.

Dr. Michelson joined Sunesis in 2006 as Senior Director and Head of Clinical Science, Oncology, bringing more than a decade of experience as a medical oncologist and in drug development in both industry and academic settings. Newly promoted to the position of Vice President, Clinical Strategy, he will oversee the clinical development of Sunesis' novel cancer therapeutics, with an emphas
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 Oramed Pharmaceuticals Inc. ... focused on the development of oral drug delivery systems, ... will present at FireRock Capital,s Micro-Cap Conference. ... Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am EST ... York City , About The ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... Al Khaimah, UAE (PRWEB) October 22, 2014 ... game-changing life science and healthcare projects, announces the addition ... MRCGP DRCOG DCH to its advisory team. Dr. Siddiqui ... advisory team. , A graduate of University ... Siddiqui was subsequently degreed in medicine in 2001. With ...
Breaking Biology Technology:Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... “What part of ... Barry Friedberg, MD. “Is the ASA not as smart as a fifth grader?” , ... (PRWEB) March 9, 2010 -- One ... relentless pursuit of patient safety ., , , , ,Yet no answer has been forthcoming ...
... ... ... ... ...
... ... Data-mining Platform Integrates a Variety of Data Streams into One Easy-to-use Analysis System ... (PRWEB) March 8, ... life science research, today announced Genedata Analyst™, an integrated statistical and data analysis platform ...
Cached Biology Technology:American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 2American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 2Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 4Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 5Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 6Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 2Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 3Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 4Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 5
(Date:10/17/2014)... is critical and pertinent for practicing physicians and clinicians ... epidemic. The Journal, Disaster Medicine and Public Health ... and Public Health, to surround the public, medical professionals ... moment. , On October 17, the journal published ... primer was prepared by Dr. Eric Toner, internist and ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... in the Sumatran jungle have captured first-time images of a ... into the elusive tiger,s behaviour. After a month in ... to record tigers in the Sumatran jungle caught the mother ... sniff and check out the camera trap. There are ...
... The volcanic eruptions thought responsible for Earth,s largest mass extinction ... animals 250 million years ago is still taking lives ... the first time, that the high silica content of coal ... substances in the coal to cause unusually high rates of ...
... A canine chromosome 7 locus that confers a high ... a collaboration between the Behavior Service at the Cummings ... at the University of Massachusetts Medical School and the ... findings are published in the January 2010 edition of ...
Cached Biology News:Camera traps yield first-time film of tigress and cubs 2Camera traps yield first-time film of tigress and cubs 3Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Tachykinin (H-2)...
...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.45 micron filtration, ... This formulation insures consistently high levels of ...
Biology Products: